Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced it will present updated clinical and preclinical data at the AACR Annual Meeting. The data includes positive outcomes from the AMPLIFY-201 Phase 1 study of ELI-002, showing significant T cell responses in patients with mKRAS-driven cancers. Additionally, preclinical studies of ELI-007 and ELI-008 demonstrated substantial immune responses compared to conventional vaccines. ELTX plans to present initial ELI-002 7P clinical data in Q2 2024.
April 05, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elicio Therapeutics, Inc. (ELTX) will present promising data on ELI-002, ELI-007, and ELI-008 at the AACR Annual Meeting, indicating significant advancements in cancer vaccine development.
The positive clinical and preclinical data presented by Elicio Therapeutics for its cancer vaccine candidates, particularly ELI-002, indicate a strong potential for future success in treating mKRAS-driven cancers. This could lead to increased investor confidence and potentially positive stock price movement in the short term, as the market reacts to the promising developments in the company's pipeline.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100